The Bottom Line Forty million Americans taking GLP-1 drugs for weight loss, a meaningful decline in the national obesity rate, stabilizing diabetes diagnoses, and a new Medicare program offering $50 monthly access to Wegovy and Zepbound 2026 is shaping up as an inflection point for obesity treatment in the United States
Results We included 39 pwIIH (mean age 33.6 years [SD 8.0], 92.3% female, median BMI 36.3 kg/m 2 [IQR 31.438.3]), with 13 patients being treated with GLP-1-RAs
Additionally, we did not account for potential confounding factors such as the use of other substances (e.g., caffeine, alcohol, cannabis) or sleep medications, which may have influenced the association between bedtime kratom use and sleep outcomes
Surgical colectomy becomes necessary in approximately 10-15% of patients with contemporary medical therapy, though rates vary by disease severity and treatment era
Initial monitoring is typically more frequent, with intervals extending once treatment is stable
Constipation, while less common than diarrhea, may also occur and can be particularly problematic in patients with pre-existing constipation issues
